J

uno Therapeutics lags behind Gilead Sciences and Novartis in developing a CAR-T gene therapy to treat adults with an aggressive form of blood cancer — but preliminary data released Wednesday suggest that Juno’s therapy, known as JCAR017, might be the most effective.

Nearly three-quarters of patients treated with a high dose of JCAR017 were free of cancer after three months. When a lower, less effective, dose of JCAR017 is included in the analysis, the complete remission rate at three months was 50 percent, according to updated results from an ongoing clinical trial that Juno refers to as TRANSCEND.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I relapsed 10 months after receiving this Juno treatment so let us not jump on the Juno bandwagon so quick. When they eliminate chemo from their protocol and get the same 3 month response, then let us praise Juno. Juno has no patient assistance program like I have found with Merck and Keytruda. There was no one to help me deal with the side effects of the treatment at Juno. Merck has nurses to take my call and answer my questions and I have an assigned nurse to my case. Merck is really there to help me and my oncologist.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.